<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: West Nile mosquito pool found in Rye</title>
	<atom:link href="http://health.lohudblogs.com/2008/08/07/west-nile-mosquito-pool-found-in-rye/feed/" rel="self" type="application/rss+xml" />
	<link>http://health.lohudblogs.com/2008/08/07/west-nile-mosquito-pool-found-in-rye/</link>
	<description>A blog about health and healthy living</description>
	<lastBuildDate>Mon, 23 Nov 2009 03:49:05 -0800</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: David Moskowitz MD</title>
		<link>http://health.lohudblogs.com/2008/08/07/west-nile-mosquito-pool-found-in-rye/comment-page-1/#comment-1311</link>
		<dc:creator>David Moskowitz MD</dc:creator>
		<pubDate>Thu, 07 Aug 2008 21:56:40 +0000</pubDate>
		<guid isPermaLink="false">http://health.lohudblogs.com/2008/08/07/west-nile-mosquito-pool-found-in-rye/#comment-1311</guid>
		<description>My biotech company, GenoMed, has had encouraging results treating West Nile virus encephalitis since 2003.

Weâ€™ve had 82% treatment success rate in people (23 of 28 improved), 75% in horses (6 of 8 survived), and 50% in birds (6 of 12 survived). Our first 8 human WNV patients were published in a peer-reviewed medical journal in 2004 (1), so our treatment officially exists in both the medical and legal senses.

Weâ€™re eager to see if our approach works again this year. Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the &quot;West Nile trial&quot; link on our companyâ€™s homepage at www.genomed.com.

Dave Moskowitz MD
CEO &amp; Chief Medical Officer
GenoMed, Inc. (Ticker symbol GMED on OTC Pink Sheets)
www.genomed.com
â€œThe public health companyâ„¢â€

1. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=investor&amp;drill=publications)</description>
		<content:encoded><![CDATA[<p>My biotech company, GenoMed, has had encouraging results treating West Nile virus encephalitis since 2003.</p>
<p>Weâ€™ve had 82% treatment success rate in people (23 of 28 improved), 75% in horses (6 of 8 survived), and 50% in birds (6 of 12 survived). Our first 8 human WNV patients were published in a peer-reviewed medical journal in 2004 (1), so our treatment officially exists in both the medical and legal senses.</p>
<p>Weâ€™re eager to see if our approach works again this year. Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the &#8220;West Nile trial&#8221; link on our companyâ€™s homepage at <a href="http://www.genomed.com" rel="nofollow">http://www.genomed.com</a>.</p>
<p>Dave Moskowitz MD<br />
CEO &#038; Chief Medical Officer<br />
GenoMed, Inc. (Ticker symbol GMED on OTC Pink Sheets)<br />
<a href="http://www.genomed.com" rel="nofollow">http://www.genomed.com</a><br />
â€œThe public health companyâ„¢â€</p>
<p>1. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: <a href="http://www.genomed.com/index.cfm?action=investor&#038;drill=publications)" rel="nofollow">http://www.genomed.com/index.cfm?action=investor&#038;drill=publications)</a></p>
]]></content:encoded>
	</item>
</channel>
</rss>
